PRMT7

Across TCGA pan-cancer cohorts, PRMT7 RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated PRMT7 data layer compared with 4 for mutation status and 5 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher PRMT7 RNA is associated with better overall survival. In most high-consensus cancer types, elevated PRMT7 expression acts as an unfavorable survival marker, although some lineages such as MESO and UCEC show a favorable association.

MESO, UCEC, and LUSC are the cancer types where PRMT7 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Quartile	All	0.644	0.349	.007	41	view →
UCEC	OS	Median	All	0.778	0.548	<.001	40	view →
LUSC	DFS	Median	III,IV	0.223	0.896	<.001	37	view →
ACC	DFS	Median	II,III,IV	0.410	0.661	.009	30	view →
SKCM	OS	Quartile	All	0.269	0.600	.001	25	view →
HNSC	OS	Median	All	0.632	0.777	.003	24	view →
BLCA	OS	Quartile	IV	0.317	0.545	.012	16	view →
LIHC	DFS	Median	All	0.489	0.592	.006	14	view →
CHOL	DFS	Median	III,IV	0.647	0.127	.006	13	view →
READ	OS	Median	All	0.935	0.329	.011	12	view →
SCLC	DFS	Quartile	III,IV	0.538	0.165	.022	11	view →
THYM	OS	Tertile	All	1.000	0.535	.002	10	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 23 lineages.

PRMT7–MESO (OS)

Open the MESO breakdown →